American Journal of BioMedicine Volume 2, Issue 8, pages 899-913, August 2014
References
1. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Seminars in Immunology 2009; 21(4): 242–253. [PubMed]
2. Liew FY, Xu D, Brint EK, O'Neill LAJ. Negative regulation of Toll-like receptor-mediated immune responses. Nature Reviews Immunology 2005;5(6): 446–458. [PubMed]
3. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006;84:712–725. [PubMed]
4. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004;430(6996):257. [PubMed]
5. Mollen KP, Anand RJ, Tsung A, et al. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006;26:430–437. [PubMed]
6. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010;48:1121–1132. [PubMed]
7. Arbibe L, Mira JP, Teusch N, et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 2000;1:533–540. [PubMed]
8. Everett W. Austin EW, Yousif NG, Ao L, Cleveland JC, Fullerton DA, Meng X. Ghrelin reduces myocardial injury following global ischemia and reperfusion via suppression of myocardial inflammatory response. American Journal of Biomedicine 2013;1:38-48. [Abstract/Full-Text]
9. Drage MG, Pecora ND, Hise AG, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 2009;258:29. [PubMed]
10. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006;84:712–725. [PubMed]
11. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001; 502; 21–24. [PubMed]
12. Sun W, Kesavan K, Schaefer B, Garrington TP, Ware M, Lassignal N, Gelfand EW, Johnson GL. MEKK2 Associates with the Adapter Protein Lad/RIBP and Regulates the MEK5-BMK1/ERK5 Pathway. J. Biol. Chem 2001; 276: 5093–5100. [Abstract/Full-Text]
13. Su C, Sun F, Cunningham RL, Rybalchenko N, Singh M. ERK5/KLF4 signaling as a common mediator of the neuroprotective effects of both nerve growth factor and hydrogen peroxide preconditioning. Age (Dordr) 2014; 36(4):9685. [PubMed]
14. Heo KS, Cushman HJ, Akaike M, Woo CH, Wang X, Qiu X, Fujiwara K, Abe J. ERK5 Activation in Macrophages Promotes Efferocytosis and Inhibits Atherosclerosis. Circulation 2014;130(2):180-91. [PubMed]
15. Yousif NG, Al-amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC cardiovascular disorders 2011; 11(1): 62. [Abstract/Full-Text]
16. Bera A, Das F, Ghosh-Choudhury N, Li X, Pal S, Gorin Y, Kasinath BS, Abboud HE, Ghosh Choudhury G. A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF. Am J Physiol Cell Physiol 2014; 306(11): C1089-100. [PubMed]
17. Kuss M, Adamopoulou E, Kahle PJ. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages. J Neurochem. 2014;129(6):980-7. [PubMed]
18. Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, Choi HG, Wang J, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem 2013;70:758-67. [PubMed]
19. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, et al. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395: 713–716. [PubMed]
20. Girio A, Montero JC, Pandiella A, Chatterjee S. Erk5 is activated and acts as a survival factor in mitosis. Cell Signal 2007; 19: 1964–1972. [PubMed]
21. N Yousif. Novel therapeutic role of siglec-E in down-regulation TLR4-mediated inflammatory response after global myocardial ischemia and reperfusion. Cardiovascular research 2014;103 (suppl 1):S90-S90. [Abstract]
22. Pearson G, English JM, White MA, Cobb MH. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 2001; 276: 7927–7931. [PubMed]
23. Dinev D, Jordan BW, Neufeld B, Lee JD, Lindemann D, et al. Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. EMBO Rep 2001; 2: 829–834. [PubMed]
24. Liu L, Cundiff P, Abel G, Wang Y, Faigle R, et al. Extracellular signal-regulated kinase (ERK) 5 is necessary and sufficient to specify cortical neuronal fate. Proc Natl Acad Sci USA 2006;103: 9697–9702. [PubMed]
25. Kato Y, Kravchenko VV, Tapping RI, Han JH, Ulevitch RJ, et al. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997; 16: 7054–7066. [PubMed]
26. Yousif NG, Ao L, Li J, Aly A, Austin E, Fullerton DA, Meng X. Myocardial Tissue TLR4 Plays a Major Role in Mediating Myocardial Injury Following Cold Ischemia and Reperfusion Through Up-regulation Of MCP-1. Journal of Surgical Research 2011;165(2): 181. [Google Scholar]
27. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. See comment in PubMed Commons below EMBO Rep 2006;7(8):782-6. [PubMed]
28. Fincham VJ, James M, Frame MC, Winder SJ. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBO J 2000; 19: 2911-2923. [PubMed]
